BACKGROUND: Secretory carcinoma (SC), originally described as mammary analogue SC, is a predominantly low-grade salivary gland neoplasm characterized by a recurrent t(12;15)(p13;q25) translocation, resulting in ETV6-NTRK3 gene fusion. Recently, alternative ETV6-RET, ETV6-MAML3, and ETV6-MET fusions have been found in a subset of SCs lacking the classic ETV6-NTRK3 fusion transcript, but still harboring ETV6 gene rearrangements. DESIGN: Forty-nine cases of SC revealing typical histomorphology and immunoprofile were analyzed by next-generation sequencing using the FusionPlex Solid Tumor kit (ArcherDX). All 49 cases of SC were also tested for ETV6, RET, and NTRK3 break by fluorescence in situ hybridization and for the common ETV6-NTRK3 fusions using reverse transcription polymerase chain reaction. RESULTS: Of the 49 cases studied, 37 (76%) occurred in the parotid gland, 7 (14%) in the submandibular gland, 2 (4%) in the minor salivary glands, and 1 (2%) each in the nasal mucosa, facial skin, and thyroid gland. SCs were diagnosed more frequently in males (27/49 cases; 55%). Patients' age at diagnosis varied from 15 to 80 years, with a mean age of 49.9 years. By molecular analysis, 40 cases (82%) presented the classic ETV6-NTRK3 fusion, whereas 9 cases (18%) revealed an alternate fusion. Of the 9 cases negative for the ETV6-NTRK3 fusion, 8 cases presented with ETV6-RET fusion. In the 1 remaining case in the parotid gland, next-generation sequencing analysis identified a novel VIM-RET fusion transcript. In addition, the analysis indicated that 1 recurrent high-grade case in the submandibular gland was positive for both ETV6-NTRK3 and MYB-SMR3B fusion transcripts. CONCLUSIONS: A novel finding in our study was the discovery of a VIM-RET fusion in 1 patient with SC of the parotid gland who could possibly benefit from RET-targeted therapy. In addition, 1 recurrent high-grade case was shown to harbor 2 different fusions, namely, ETV6-NTRK3 and MYB-SMR3B. The expanded molecular spectrum provides a novel insight into SC oncogenesis and carries important implications for molecular diagnostics, as this is the first SC-associated translocation with a non-ETV6 5' fusion partner. This finding further expands the definition of SC while carrying implications for selecting the appropriate targeted therapy.

Biomedical Center Faculty of Medicine in Plzen Charles University

Biopticka Laboratory Ltd

Department of Oral Pathology Faculty of Dentistry University of São Paulo São Paulo Brazil

Department of Pathology

Department of Pathology and Laboratory Medicine University of Calgary Calgary Laboratory Services Foothills Medical Centre Calgary AB Canada

Department of Pathology Southern California Permanente Medical Group Woodland Hills CA

Department of Pathology University of Alabama at Birmingham Birmingham AL

Diagnostic and Research Institute of Pathology Medical University of Graz Graz Austria

Institute of Biomedicine Pathology University of Turku Turku Finland

Molecular Genetic Laboratory Biopticka Laboratory Ltd Plzen Czech Republic

See more in PubMed

Skalova A, Vanecek T, Sima R, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010;34:599–608.

Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2:367–376.

Knezevich SR, McFadden DE, Tao W, et al. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998;18:184–187.

Knezevich SR, Garnett MJ, Pysher TJ, et al. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res. 1998;15:5046–5048.

Leeman-Neill RJ, Kelly LM, Liu P, et al. ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer. Cancer. 2014;120:799–807.

Kralik JM, Kranewitter W, Boesmueller H, et al. Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia. Diagn Pathol. 2011;6:19.

Skalova A, Bell D, Bishop JA, et alEl-Naggar A, Chan JKC, Grandis JR, Takata T, Slootweg PJ. Secretory carcinoma. World Health Organization (WHO) Classification of Head and Neck Tumours, 4th edition. IARC Press, Lyon, France. 2017:177–178.

Skalova A. Mammary analogue secretory carcinoma of salivary gland origin: an update and expanded morphologic and immunohistochemical spectrum of recently described entity. Head Neck Pathol. 2013;7:S30–S36.

Skalova A, Gnepp DR, Lewis JS Jr, et al. Newly described entities in salivary gland pathology. Am J Surg Pathol. 2017;41:e33–e47.

Griffith C, Seethala R, Chiosea SI. Mammary analogue secretory carcinoma: a new twist to the diagnostic dilemma of zymogen granule poor acinic cell carcinoma. Virchows Arch. 2011;459:117–118.

Fehr A, Loning T, Stenman G. Mammary analogue secretory carcinoma of the salivary glands with ETV6-NTRK3 gene fusion. Letter to the editor. Am J Surg Pathol. 2011;35:1600–1602.

Connor A, Perez-Ordoñez B, Shago M, et al. Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity. Am J Surg Pathol. 2012;36:27–34.

Majewska H, Skalova A, Stodulski D, et al. Mammary analogue secretory carcinoma of salivary glands: a new entity associated with ETV6 gene rearrangement. Virchows Arch. 2015;466:245–254.

Bishop JA. Unmasking MASC: bringing to light the unique morphologic, immunohistochemical and genetic features of the newly recognized mammary analogue secretory carcinoma of salivary glands. Head Neck Pathol. 2013;7:35–39.

Bishop JA, Yonescu R, Batista D, et al. Most nonparotid “acinic cell carcinomas” represent mammary analog secretory carcinomas. Am J Surg Pathol. 2013;37:1053–1057.

Hernandez-Prera JC, Holmes BJ, Valentino A, et al. Macrocystic (mammary analogue) secretory carcinoma an unusual variant and a pitfall in the differential diagnosis of cystic lesions in the head and neck. Am J Surg Pathol. 2019;43:1483–1492.

Bishop JA, Taube JM, Su A, et al. Secretory carcinoma of the skin harboring ETV6 gene fusions. A cutaneous analogue to secretory carcinomas of the breast and salivary glands. Am J Surg Pathol. 2017;41:62–66.

Kazakov DV, Hantschke M, Vanecek T, et al. Mammary-type secretory carcinoma of the skin. Am J Surg Pathol. 2010;34:1226–1227.

Hyrcza MD, Ng T, Crawford RI. Detection of the ETV6-NTRK3 translocation in cutaneous mamary-analogue secretory carcinoma. Diagn Histopathol. 2015;21:481–484.

Lurquin E, Jorissen M, Debiec-Rychter M, et al. Mammary analogue secretory carcinoma of the sinus ethmoidalis. Histopathology. 2015;67:749–751.

Baneckova M, Agaimy A, Andreassen S, et al. Mammary analog secretory carcinoma of the nasal cavity: characterization of 2 cases and their distinction from other low-grade sinonasal adenocarcinomas. Am J Surg Pathol. 2018;42:735–743.

Xu B, Aryeequaye R, Wang L, et al. Sinonasal secretory carcinoma of salivary gland with high grade transformation: a case report of this under-recognized diagnostic entity with prognostic and therapeutic implications. Head Neck Pathol. 2018;12:274–278.

Reynolds S, Shaheen M, Olson G, et al. A case of primary mammary analog secretory carcinoma (MASC) of the thyroid masquerading as papillary thyroid carcinoma: potentially more than a one off. Head Neck Pathol. 2016;10:405–413.

Dettloff J, Seethala RR, Stevens TM, et al. Mammary analog secretory carcinoma (MASC) involving the thyroid gland: a report of the first 3 cases. Head Neck Pathol. 2017;11:124–130.

Dogan S, Wang L, Ptashkin RN, et al. Mammary analog secretory carcinoma of the thyroid gland: a primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion. Mod Pathol. 2016;29:985–995.

Huang T, McHugh JB, Berry GJ, et al. Primary mammary analogue secretory carcinoma of the lung: a case report. Hum Pathol. 2018;74:109–113.

Ito Y, Ishibashi K, Masaki A, et al. Mammary analogue secretory carcinoma of salivary glands: a clinicopathological and molecular study including 2 cases harboring ETV6-X fusion. Am J Surg Pathol. 2015;39:602–610.

Skalova A, Vanecek T, Simpson RHW, et al. Mammary analogue secretory carcinoma of salivary glands. Molecular analysis of 25 ETV6 gene rearranged tumors with lack of detection of classical ETV6-NTRK3 fusion transcript by standard RT-PCR: report of 4 cases harboring ETV6-X gene fusion. Am J Surg Pathol. 2016;40:3–13.

Skalova A, Vanecek T, Martinek P, et al. Molecular profiling of mammary analogue secretory carcinoma revealed a subset of tumors harboring a novel ETV6-RET translocation: report of 10 cases. Am J Surg Pathol. 2018;42:234–246.

Rooper LM, Karantanos T, Ning Y, et al. Salivary secretory carcinoma with a novel ETV6-MET fusion: expanding the molecular spectrum of a recently described entity. Am J Surg Pathol. 2018;42:1121–1126.

Guilmette J, Dias-Santagata D, Nose V, et al. Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family. Hum Pathol. 2019;83:50–58.

Miesbauerová M, Tommola S, Šteiner P, et al. Cytopathological features of secretory carcinoma of salivary glands and ancillary techniques in its diagnostics: impact of new Milan system for reporting salivary gland cytopathology. APMIS. 2019;127:491–502.

Stevens TM, Kovalovsky AO, Velosa C, et al. Mammary analog secretory carcinoma, low-grade salivary duct carcinoma, and mimickers: a comparative study. Mod Pathol. 2015;28:1084–1100.

Skalova A, Vanecek T, Majewska H, et al. Mammary analogue secretory carcinoma of salivary glands with high grade transformation: report of three cases with the ETV6-NTRK3 gene fusion and analysis of TP53, beta-catenin, EGFR and CCND1 genes. Am J Surg Pathol. 2017;38:23–33.

Kummar S, Lassen UN. TRK inhibition: a new tumor agnostic treatment strategy. Targeted Oncology. 2018;13:545–556.

Drilon A. TRK inhibitors in TRK fusion-positive cancers. Ann Oncol. 2019;30(suppl 8):viii23–viii30.

Skalova A, Santana Conceição T, Vanecek T, et al. Salivary secretory carcinoma with a novel VIM-RET fusion: NGS based molecular profiling of 49 cases revealed an expanding molecular spectrum of a recently described entity United States & Canadian Academy of Pathology Annual Meeting 2019/03/01. Mod Pathol. 2019;32:1–59.

Li AY, McCusker MG, Russo A, et al. RET fusions in solid tumors. Cancer Treat Rev. 2019;81:101911.

Shah AA, Wenig BM, LeGallo RD, et al. Morphology in conjunction with immunohistochemistry is sufficient for the diagnosis of mammary analogue secretory carcinoma. Head Neck Pathol. 2015;9:85–95.

Skálová A, Ptáková N, Santana T, et al. NCOA4-RET and TRIM27-RET are characteristic gene fusions in salivary intraductal carcinoma, including invasive and metastatic tumors. Is intraductal correct? Am J Surg Pathol. 2019;43:1303–1313.

Skalova A, Vanecek T, Uro-Coste E, et al. Molecular profiling of salivary gland intraductal carcinoma revealed a subset of tumors harboring NCOA4-RET and novel TRIM27-RET fusions: a report of 17 cases. Am J Surg Pathol. 2018;42:1445–1455.

Weinreb I, Zhang L, Tirunagari LM, et al. Novel PRKD gene rearrangements and variant fusions in cribriform adenocarcinoma of salivary gland origin. Genes Chromosomes Cancer. 2014;53:845–856.

Antonescu CR, Katabi N, Zhang L, et al. EWSR1-ATF1 fusion is a novel and consistent finding in hyalinizing clear-cell carcinoma of salivary gland. Genes Chromosomes Cancer. 2011;50:559–570.

Seethala RR, Dacic S, Cieply K, et al. A reappraisal of the MECT1/ MAML2 translocation in salivary mucoepidermoid carcinomas. Am J Surg Pathol. 2010;34:1106–1121.

Jee KJ, Persson M, Heikinheimo K, et al. Genomic profiles and CRTC1-MAML2 fusion distinguish different subtypes of mucoepidermoid carcinoma. Mod Pathol. 2013;26:213–222.

Brill LB II, Kanner WA, Fehr A, et al. Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms. Mod Pathol. 2011;24:1169–1176.

Na K, Hernandez-Prera JC, Lim JY, et al. Characterization of novel genetic alterations in salivary gland secretory carcinoma. Mod Pathol. 2020;33:541–550.

Kastnerova L, Luzar B, Goto K, et al. Secretory carcinoma of the skin report of 6 cases, including a case with a novel NFIX-PKN1 translocation. Am J Surg Pathol. 2019;43:1092–1098.

Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68:3033–3046.

Kato S, Subbiah V, Marchlik E, et al. RET aberrations in diverse cancers: next-generation sequencing of 4871 patients. Clin Cancer Res. 2017;23:1988–1997.

Huang SC, Zhang L, Sung YS, et al. Frequent FOS gene rearrangements in epithelioid hemangioma: a molecular study of 58 cases with morphologic reappraisal. Am J Surg Pathol. 2015;39:1313–1321.

Ma Y, Miao Y, Peng Z, et al. Identification of mutations, gene expression changes and fusion transcripts by whole transcriptome RNAseq in docetaxel resistant prostate cancer cells [published correction appears in Springerplus. 2016 Dec 8;5(1):2084]. Springerplus. 2016;5:1861.

Stenman G, Andersson MK, Andren Y. New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer. Cell Cycle. 2010;9:2986–2995.

Discovery of Novel TULP4/ACTN4/EWSR1/ACTB::MYB and ESRRG::DNM3 Fusions Expands Molecular Landscape of Adenoid Cystic Carcinoma Beyond Fusions Between MYB/MYBL1 and NFIB Genes

Molecular pathology in diagnosis and prognostication of head and neck tumors

SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets